- Research article
- Open Access
- Open Peer Review
Dual-energy computed tomography has limited sensitivity for non-tophaceous gout: a comparison study with tophaceous gout
BMC Musculoskeletal Disordersvolume 17, Article number: 91 (2016)
Dual-energy computed tomography (DECT) is a new diagnostic tool for gout, but its sensitivity has not been established. Our goal was to assess the sensitivity of DECT for the detection of monosodium urate (MSU) deposits in non-tophaceous and tophaceous gout, both at the level of the patient and that of the individual joint or lesion.
DECT was performed on 11 patients with crystal-proven non-tophaceous gout and 10 with tophaceous gout and included both the upper and lower extremities in 20/21 patients. DECT images were simultaneously acquired at 80 and 140 kV and then processed on a workstation with proprietary software using a two-material decomposition algorithm. MSU deposits were color coded as green by the software and fused onto grey-scale CT images. The number and location of these deposits was tallied independently by two DECT-trained radiologists blinded to the clinical characteristics of the patient. Sensitivity of DECT was defined as the proportion of patients with a confirmed diagnosis of gout which was correctly identified as such by the imaging technique. All patients provided informed consent to participate in this IRB-approved study.
MSU deposits were detected by DECT in ≥1 joint area in 7/11 (64 %) patients with non-tophaceous gout, but were only detected in 3/12 (25 %) joints proven by aspiration to be affected with gout. Inclusion of the upper extremity joints in the scanning protocol did not improve sensitivity. All 10 patients with tophaceous gout had MSU deposits evident by DECT. The sensitivity of DECT for individual gouty erosions was assessed in 3 patients with extensive foot involvement. MSU deposits were detected by DECT within or immediately adjacent to 13/26 (50 %) erosions.
A DECT protocol that includes all lower extremity joints has moderate sensitivity in non-tophaceous and high sensitivity in tophaceous gout. However, DECT has lower sensitivity when restricted to individual crystal-proven gouty joints in non-tophaceous disease or individual erosive lesions in tophaceous gout. The detection of MSU deposits by DECT relates to their size and density and the detection parameters of the DECT scanner and adjustment of the latter might improve sensitivity.
Gout is an inflammatory arthritis characterized by the deposition of monosodium urate (MSU) crystals in joints, cartilage, and soft tissues . The untreated disease can lead to formation of tophi, chronic synovitis, and joint damage [1, 2]. Thus, the establishment of a diagnosis and initiation of therapy early in disease are essential to the maintenance of normal function and quality of life. Demonstrating MSU crystals in the joint fluid or in a tophus is the gold standard for gout diagnosis. However, many health care providers do not perform arthrocenteses and the identification of MSU crystals can be challenging, especially in early disease. In the absence of MSU crystal demonstration in joint or tophus aspirates, clinical, radiographic, and laboratory criteria can be helpful in diagnosis. However, characteristic radiographic findings are only seen late in the disease, including “punched-out” erosions with overhanging edges and sclerotic margins, often in association with asymmetric soft tissue masses [3, 4]. Various advanced imaging techniques are being utilized, including ultrasonography with power Doppler, magnetic resonance imaging (MRI), and conventional computed tomography (CT). Each has their unique advantages and disadvantages. However, none are specific enough to facilitate or confirm a diagnosis of gout . Dual-energy CT (DECT) is a new technique that allows identification of MSU crystal deposits. With this imaging methodology, the compositions of different tissues are determined by analyzing the difference in attenuation in a material exposed simultaneously to two different X-ray spectra. It has high accuracy and sensitivity for the identification of MSU and calcium kidney stones . Whereas its sensitivity has been reported to be 100 % for clinically-overt tophaceous disease [7–9], its sensitivity has not been fully established for non-tophaceous disease where its diagnostic utility would be the greatest.
Our goal was to assess the sensitivity of DECT for the detection of monosodium urate (MSU) deposits in non-tophaceous and tophaceous gout, both at the level of the patient and that of the individual joint or lesion.
We studied 21 patients with gout as defined by the American College of Rheumatology preliminary criteria . With one exception, all patients were recruited from the clinical practice of one of the authors (ANB) and underwent a comprehensive musculoskeletal examination at the time of recruitment. The patients included 1) 11 with non-tophaceous gout, defined by the demonstration of MSU crystals on a joint aspirate [performed in 10 of the 11 patients by one of the authors (ANB)] and the absence of tophi on physical examination or erosions on available radiographs and 2) 10 with tophaceous gout, defined by one or more of the following: the presence of palpable tophi (n = 5), the presence of characteristic radiographic erosions (n = 7), or gross MSU deposits in a surgical specimen (n = 3).
The Johns Hopkins Medicine Institutional Review Boards approved the study. All patients provided written informed consent before inclusion in the study.
Each patient underwent DECT of their hands, wrists, elbows, knees, ankles, and feet using the imaging protocol described below. The initiation of urate-lowering therapy (ULT) was not withheld in treatment-naïve patients, although the scan was completed as soon as possible after ULT was initiated. Each patient underwent a comprehensive musculoskeletal examination. Clinical data obtained for this study included demographics (age, gender, ethnicity), gout history (duration of disease, therapeutic interventions, frequency of gout flares), arthrocentesis if the disease was not previously crystal-proven, radiographs performed as part of the clinical assessment, and laboratory evaluation including serum urate levels.
Dual-energy computed tomography protocol
DECT images were obtained of the four limbs scanned in pairs: the hands/wrists, feet/ankles, elbows, and knees. With each scan, the patient was positioned so that the relevant joints were in a central location within the dual energy field. Each joint area had a scan field which ensured that all articulations were visualized in full and included a minimum of 4 cm of adjacent extremity for the elbow, knees, wrists, and ankles. Scans were performed using a dual-source DECT scanner (SOMATOM Definition Flash Dual-Source CT scanner; Siemens Healthcare, Forchheim, Germany). Parameters were 80/Sn140 kVp and 211 mAs for tube A with tube B automatically adjusted to maintain a 2:1 ratio. Collimation of 0.6 mm was reconstructed to yield a 0.75-mm slice thickness. A material decomposition algorithm was performed on a multi-modality workspace (SW-Version VE52 Siemens Healthcare) using Siemens syngo.via dual-energy software package (SW-Version VA20). The material-specific difference in attenuation of urate between the two energy levels at 80- and Sn140-kV allowed accurate detection of MSU, which was then color coded as green and fused onto the standard greyscale CT image. These could be reviewed as both 2D cross-sectional and 3D surface rendered images. The threshold ratio parameter was set at 1.36, with a range of Hounsfeld units of 150 – 500 HU.
Each DECT scan was read by two of three musculoskeletal or CT radiologists (EKF, JAC, or UT, with 32, 16, and 1 years of experience, respectively) and scored with respect to the presence and number of MSU deposits at each joint. For cases in which a discrepancy existed, agreement was reached by consensus. These radiologists were blinded to the clinical characteristics of the patients and trained to exclude known artifacts, including those related to nailbeds, skin, metal prostheses, and beam hardening, from their analyses .
Descriptive statistics were used to characterize the baseline features of the cohort. Proportions were used to summarize categorical variables and median [range] or mean [standard deviation] for continuous variables. The Wilcoxon rank-sum test was used to compare continuous variables and the two-sided Fisher exact test was used to compare categorical variables. Correlations between continuous variables were tested using the Spearman rank correlation coefficient. Sensitivity of DECT was defined as the proportion of patients with a confirmed diagnosis of gout (or specific joint involved by gout) which was correctly identified as such by the imaging technique. P values less than 0.05 were considered statistically significant. Analyses were conducted using JMP (Version 11, SAS Institute Inc., Cary, NC).
Demographic and clinical characteristics
The demographic and clinical characteristics of the patients at the time of DECT are summarized in Table 1. The study patients included 17 men and four women with a median age of 59 years (range, 43–89 years). There was no significant difference in age between the patients with non-tophaceous and tophaceous gout. The median duration of gout was 0.8 years (range 0.2-13 years) for the non-tophaceous gout patients and 10.2 years (range 1–28 years) for those with tophaceous gout. Among the 11 non-tophaceous gout patients, seven had had gout for less than one year and nine had had more than one gout attack. The maximum recorded serum urate value was higher for the tophaceous than the non-tophaceous gout patients, a difference that did not reach statistical significance (median value, 594.8 vs 529.4 μmol/L, p = 0.18).
Among the 11 non-tophaceous gout patients, MSU crystals were demonstrated in 12 joint aspirates, including those of the 1st metatarsophalangeal (n = 7), knee (n = 2), ankle (n = 2), and metacarpophalangeal (n = 1) joints (Table 2). The median interval between these joint aspirations and DECT was 37 days (range, 21 – 149). At the time of DECT, nine of these 11 patients were on ULT with a median duration of 41 days (range 6–126 days). Serum urate values obtained within 30 days of DECT were < 6 mg/dl in three of eight patients.
Among the 10 tophaceous gout patients, five had palpable tophi, three with associated radiographic erosions and one with tophaceous material in a surgical specimen (Table 3). The remaining five patients had tophaceous material in a surgical specimen (n = 2) or characteristic erosions on radiographs (n = 4). Seven of the 10 patients with tophaceous gout had had their diagnosis confirmed by microscopic demonstration of MSU crystals.
DECT scanning in non-tophaceous gout
Among the 11 patients with non-tophaceous gout, seven (64 %) had MSU deposits detected by DECT of both upper and lower extremity joints (Table 2). The MSU deposits were present in only three of the 12 joints (25 %) shown to have MSU crystals by polarized light microscopic analysis of aspirated material. MSU deposits were present in the elbows of three patients, but in each of these they were also found in one or more lower extremity joints.
In a comparison of the patients with and without MSU deposits by DECT, the median age of the seven patients with deposits was 57 years and that of the four patients without deposits was 66 years (p = 0.07, Wilcoxon rank sum test). There were no significant differences in duration of clinical gout or maximum serum urate value between the two groups. Among the nine patients on ULT at the time of the scan, there was no significant difference in the duration of this therapy between the seven with and the two patients without MSU deposits.
The number of MSU deposits ranged from 1–15 (median 3) among the seven patients with positive DECT. The number of these deposits did not correlate significantly with the maximum serum urate level.
DECT scanning in tophaceous gout
MSU deposits were evident by DECT in each of the 10 patients (100 %) with tophaceous gout (Table 3). We sought to determine the correlation between MSU deposits on DECT with tophi evident by clinical examination or by the presence of characteristic erosions on radiographs or CT images. Of the five patients with palpable tophi, a correlative analysis could be performed on three (one patient had his solitary tophus surgically excised and the other had DECT of only the lower extremities). In these three patients (numbers 15, 19, 20), there were 25 discrete palpable tophi. Corresponding MSU deposits were detected with DECT in 19 (76 %). An example of this is shown in Fig. 1. This patient had soft tissue masses around the metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints of his hand, evident both by palpation and by 3D-volume rendering of the CT images. MSU deposits evident by DECT largely conformed to these soft tissue masses, but were sparse in some affected joints and absent in others (e.g. little finger DIP and long finger PIP joints).
Ten discrete osseous erosions were evident on radiographs obtained on affected joints of seven patients prior to DECT. MSU deposits were evident at the site of seven of these erosions. An example of metatarsal head erosion not associated with MSU deposits by DECT is shown in Fig. 2. In this patient, ultrasonography demonstrated fluffy hyperechoic material in the synovial space, suggestive of tophaceous material.
Three patients had extensive erosions in their feet, evident by CT and defined by a well-defined cortical break and overhanging edges. At the time of DECT scan, two had initiated urate-lowering therapy 34–100 days before the scan, but none of the three had a serum urate level <6.8 mg/dl. By fusing the dual-energy processing with the CT images, we tabulated the number of erosions with and without corresponding MSU deposits in the erosion cavity or in the surrounding soft tissue mass. Among these three patients, there were 26 erosions, only 13 (50 %) of which had associated MSU deposits. This failure to detect MSU deposits could not be overcome by changing the lower limit of the density threshold of the DECT from 150 to 135 Hounsfield units. An example of a large erosion evident by CT and lacking associated MSU deposits is shown in Fig. 3.
The diagnostic utility of DECT in the evaluation of arthritis hinges on its ability to detect MSU deposits in patients with various stages of gout. In the current study, we compared the sensitivity of DECT in patients with crystal-proven, non-tophaceous gout and those with tophaceous gout, with or without radiographic erosions. In our 11 patients with non-tophaceous gout, DECT of joints in all four extremities demonstrated MSU deposits in seven, equating to an overall sensitivity of 64 %. Importantly, these deposits were only detected in three of 12 (25 %) joints shown to have MSU deposits by aspiration and polarized light microscopic analysis of the synovial fluid or soft tissue material. In this small series of seven non-tophaceous gout patients with MSU deposits detected by DECT, inclusion of the upper extremities in the scanning protocol served to identify MSU deposits in the elbows of three, but each had concomitant deposits in their lower extremities. Thus the sensitivity of DECT was not increased by the inclusion of the upper extremities but was increased by inclusion of all lower extremity joints.
Our protocol for DECT of both the upper and lower extremities identified MSU deposits in each of our 10 patients with tophaceous gout. This 100 % sensitivity of DECT for tophaceous gout is consistent with three other studies [7–9]. However, this study highlights the limitations of DECT in identifying tophaceous deposits. Specifically, there were notable examples where MSU deposits could not be detected in areas of tophaceous deposits, either judged clinically by physical examination or by radiographic, ultrasonographic, or CT imaging. This failure to detect MSU deposits in sites of tophi could not be overcome by a change in detection thresholds of the DECT imaging software. Thus, there may be limitations in the sensitivity of DECT for defining gout as the etiology for individual erosions or periarticular soft tissue masses.
The sensitivity of DECT in crystal-proven, non-tophaceous gout has been evaluated in three other studies, with reported sensitivities ranging from 79–90 % [12–14]. In these studies, DECT was restricted to the feet , the clinically affected joint , or the most prominently involved joint regions . The sensitivity of DECT for the diagnosis of non-tophaceous gout was lower in our series of patients, particularly when judged by the detection of MSU deposits in the joints from which MSU crystals were detected by joint aspiration.
There are several potential reasons for the lower sensitivity noted in our study. First, we may have included patients with a shorter duration of gout or a lesser degree of hyperuricemia, leading to MSU crystal deposition below the threshold of detection of DECT. The reported sensitivity of DECT for the detection of MSU deposits is proportional to the stage of gout, being 0.03-24 % in asymptomatic hyperuricemia [13, 15], 79–80 % in patients with short-duration acute gout [12, 13], 84 % in long-duration (≥3 years) acute gout  and 100 % in tophaceous gout [7–9]. The limit of detection of DECT is generally considered to be 2 mm, so microscopic tophi may be missed . The mean duration of gout was shorter in our subjects compared to the participants of two other studies where these data are provided (3.1 years in our study compared to 3.8-11 years in the other studies) [13, 14]. In the study of Manger et al., only two of four patients presenting with their first gout flare had DECT evidence of MSU deposition. The mean serum urate values were comparable in our subjects to those of the other three studies, so an effect of hyperuricemia severity could not be assessed. Second, our study protocol allowed patients to initiate ULT before DECT. Nine of our 11 subjects with non-tophaceous gout were on ULT for a median of 35 days (mean 1.5 months). Eight of these had a serum urate measured within 30 days of DECT and all but three had a serum urate <6 mg/dl. However, 82 % of subjects in the study of Dalbeth et al. were on ULT for an average of 34 months . Similarly, MSU deposits were detected in 37 of 40 gout patients studied by Choi et al., despite the fact that 35 had been treated with ULT . The rate of dissolution of MSU deposits has been shown to be slow in patients on appropriately-dosed xanthine oxidase inhibitor or uricosuric therapy, as measured by clinical exam  and by DECT [9, 19]. The size of subcutaneous tophi, measured with calipers, did not change significantly over a one-year period in a clinical trial comparing febuxostat and allopurinol, despite normalization of the serum urate . Third, our imaging parameters may have been different from those of other investigators, although we used parameters established by the manufacturer as optimal for gout imaging.
The failure of DECT to detect MSU crystal deposits at sites of tophi evident by physical or pathologic examination or other imaging methods has been noted by other investigators. Although DECT identified four times more urate deposits than physical examination in the study of Choi et al., there were two patients in whom palpable tophi did not have a corresponding MSU deposit by DECT . Glazebrook et al. reported a patient with an inflamed wrist, small erosions at the head of the third metacarpal, and negative DECT but evidence of MSU crystals by joint aspiration and synovial biopsy . In a study correlating structural joint damage on radiography of the feet with DECT MSU crystal deposition, Dalbeth et al. found MSU deposits in 112/262 (43 %) joints with radiographic erosions. The prevalence of these deposits in individual joints correlated positively with the joint erosion score . In 161 gout patients studied by Hu et al., MSU deposits were evident by DECT in 121. Among the 40 with negative DECT, eight had MSU deposits evident by conventional CT . Similarly, McQueen detected tophi by MR but not by DECT in 10/150 joint sites in a study of 10 tophaceous gout patients . In the study of Huppertz et al. comparing DECT and ultrasound for the diagnosis of gout in 39 patients, MSU deposits were detected by US but not by DECT in three patients . At the level of individual joints, the disparity was more striking. As an example, MSU deposits were evident by DECT in 26 % and by ultrasound in 74 % of the 78 first metatarsophalangeal joints . Finally, Melzer et al. reported a patient with tophaceous gout who underwent DECT of her feet one week before her death . Two large soft tissue tophi, one around the ventral ankle joint and the other at the distal left great toe, had minimal to no green-coded images on DECT. At post-mortem examination, both of these soft tissue masses were confirmed to be tophi with a central crystalline core, the latter measuring at least 1 cm in one dimension in each.
There are several explanations for the occasional failure of DECT to detect MSU deposits at sites of tophi. Dalbeth et al. noted a linear relationship between erosion size and MSU crystal deposition evident by DECT, suggesting that the resolution of DECT may not be sufficient to detect small tophi . This issue would apply in particular to MSU deposits detected by ultrasound but not by DECT. The parameter ratio for DECT is set by the manufacturer to optimize differentiation of urate- and calcium-containing voxels. However, several investigators have shown that the use of a different parameter ratio can correct previously false-negative DECT scans for MSU deposits detected by conventional CT  or MR imaging . Finally, DECT may only detect dense tophi. Lockmann et al. showed that DECT did not detect MSU crystals in a sample of white synovial fluid containing a high concentration of these crystals by polarized light microscopy (i.e. “gout milk”) . In the pathologic examination conducted by Melzer et al., tophi with a density throughout most of their volume below 150 Hounsfield units were not color-coded by the DECT imaging software, thereby limiting the sensitivity of DECT for low-density tophi .
Our study was limited by the absence of control subjects to assess specificity of DECT. The small size of our study did not allow determination of the sensitivity of DECT for the entire spectrum of non-tophaceous gout, but served to illustrate the limitations of the technique in patients with early disease whose diagnosis was confirmed by joint aspiration.
In conclusion, a DECT scanning protocol that includes all lower extremity joints has moderate sensitivity in non-tophaceous and high sensitivity in tophaceous gout. However, DECT has lower sensitivity when restricted to individual crystal-proven gouty joints in non-tophaceous disease or individual erosive or tophaceous lesions in tophaceous gout. The detection of MSU deposits by DECT depends on their size and density and the detection parameters of the DECT scanner. The latter could potentially be improved with an adjustment of the parameters used to both acquire and then process the DECT images.
Ethics approval and consent to participate
The Johns Hopkins Medicine Institutional Review Boards approved the study (NA00067327). All patients provided written informed consent before inclusion in the study.
Dual-energy computed tomography
Body mass index
Girish G, Melville DM, Kaeley GS, Brandon CJ, Goyal JR, Jacobson JA, et al. Imaging appearances in gout. Arthritis. 2013;2013:673401.
Dalbeth N, Aati O, Gao A, House M, Liu Q, Horne A, et al. Assessment of tophus size: a comparison between physical measurement methods and dual-energy computed tomography scanning. J Clin Rheumatol. 2012;18:23–7.
McQueen FM, Chhana A, Dalbeth N. Mechanisms of joint damage in gout: evidence from cellular and imaging studies. Nat Rev Rheumatol. 2012;8:173–81.
Buckley TJ. Radiologic features of gout. Am Fam Physician. 1996;54:1232–8.
Tashakkor AY, Wang JT, Tso D, Choi HK, Nicolaou S. Dual-energy computed tomography: a valid tool in assessment of gout? Int J Clin Rheumatol. 2012;7:73–9.
Primak AN, Fletcher JG, Vrtiska TJ, Dzyubak OP, Lieske JC, Jackson ME, et al. Noninvasive differentiation of uric acid versus non-uric acid kidney stones using dual-energy CT. Acad Radiol. 2007;14:1441–7.
Dalbeth N, Aati O, Kalluru R, Gamble GD, Horne A, Doyle AJ, et al. Relationship between structural joint damage and urate deposition in gout: a plain radiography and dual-energy CT study. Ann Rheum Dis. 2015;74:1030–6.
Choi HK, Al-Arfaj AM, Eftekhari A, Munk PL, Shojania K, Reid G, et al. Dual energy computed tomography in tophaceous gout. Ann Rheum Dis. 2009;68:1609–12.
Rajan A, Aati O, Kalluru R, Gamble GD, Horne A, Doyle AJ, et al. Lack of change in urate deposition by dual-energy computed tomography among clinically stable patients with long-standing tophaceous gout: a prospective longitudinal study. Arthritis Res Ther. 2013;15:R160.
Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20:895–900.
Mallinson PI, Coupal T, Reisinger C, Chou H, Munk PL, Nicolaou S, et al. Artifacts in dual-energy CT gout protocol: a review of 50 suspected cases with an artifact identification guide. AJR Am J Roentgenol. 2014;203:W103–9.
Bongartz T, Glazebrook KN, Kavros SJ, Murthy NS, Merry SP, Franz 3rd WB, et al. Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study. Ann Rheum Dis. 2015;74:1072–7.
Dalbeth N, House ME, Aati O, Tan P, Franklin C, Horne A, et al. Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study. Ann Rheum Dis. 2015;74:908–11.
Manger B, Lell M, Wacker J, Schett G, Rech J. Detection of periarticular urate deposits with dual energy CT in patients with acute gouty arthritis. Ann Rheum Dis. 2012;71:470–2.
Kimura-Hayama E, Criales-Vera S, Nicolaou S, Betanzos JL, Rivera Y, Alberu J, et al. A pilot study on dual-energy computed tomography for detection of urate deposits in renal transplant patients with asymptomatic hyperuricemia. J Clin Rheumatol. 2014;20:306–9.
Glazebrook KN, Kakar S, Ida CM, Laurini JA, Moder KG, Leng S. False-negative dual-energy computed tomography in a patient with acute gout. J Clin Rheumatol. 2012;18:138–41.
Choi HK, Burns LC, Shojania K, Koenig N, Reid G, Abufayyah M, et al. Dual energy CT in gout: a prospective validation study. Ann Rheum Dis. 2012;71:1466–71.
Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47:356–60.
Wu H, Xue J, Ye L, Zhou Q, Shi D, Xu R. The application of dual-energy computed tomography in the diagnosis of acute gouty arthritis. Clin Rheumatol. 2014;33:975–9.
Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36:1273–82.
Hu HJ, Liao MY, Xu LY. Clinical utility of dual-energy CT for gout diagnosis. Clin Imaging. 2015;39:880–85.
McQueen FM, Doyle AJ, Reeves Q, Gamble GD, Dalbeth N. DECT urate deposits: now you see them, now you don't. Ann Rheum Dis. 2013;72:458–9.
Huppertz A, Hermann KG, Diekhoff T, Wagner M, Hamm B, Schmidt WA. Systemic staging for urate crystal deposits with dual-energy CT and ultrasound in patients with suspected gout. Rheumatol Int. 2014;34:763–71.
Melzer R, Pauli C, Treumann T, Krauss B. Gout tophus detection-a comparison of dual-energy CT (DECT) and histology. Semin Arthritis Rheum. 2014;43:662–5.
Löckmann V, Veit-Haibach P, Schmid L. Difficult diagnosis of gout: the benefit of dual enery computed tomography, initial experiene in routine clinical practice. Rheumatol Rep. 2013;5(e5):20–2.
This work was supported by grants from Siemens Healthcare to JAC and the National Institutes of Health [grant numbers R01 DE12354-15A1, T32 AR48522] to ANB and JWM, and a generous donation from Ms. Elizabeth Hogue. The sponsor of this research project (Siemens Medical Solutions USA, Inc) was not involved in the design and conduct, collection, management, analysis, and interpretation of the data; nor preparation, review, or approval of the manuscript.
Dr. Carrino reports grants from Siemens Medical Solutions during the conduct of the study and consulting fees from Pfizer, BioClinica, and General Electric. Dr. Baer received consulting fees (<$10,000 from each) from Glenmark Pharmaceuticals and Bristol-Myers Squibb. Dr. Fuld is an employee of Siemens Medical Solutions (the study sponsor) but did not have any role in the study design and conduct or data collection and interpretation. None of the other authors had any non-financial competing interests.
ANB participated in the design of the study, recruited patients, performed the patient examinations and joint aspirations, collected data, and drafted the manuscript. TK assisted in the patient examinations and joint aspirations, collated the study data, performed data analyses, and helped draft the manuscript. UJT interpreted the DECT scans, participated in data collection and analysis, and revised the manuscript critically. GKT participated in study design and implementation, conducted the research patient visits, administered patient questionnaires, and revised the manuscript critically. MKF assisted with the technical aspects of DECT scanning and interpretation and revised the manuscript critically. JWM planned the study, secured its funding, and revised the manuscript critically. MMD participated in the design of the study, performed the statistical analyses, and helped to draft the manuscript. EKF interpreted the DECT scans and participated in data analysis, and revised the manuscript critically. JAC conceived the study, secured its funding, participated in its design and implementation, interpreted the DECT scans, and revised the manuscript critically. All authors read and approved the final manuscript and are accountable for all aspects of the work.